BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Leeuwen L, Fitzgerald DA, Gaskin KJ. Liver disease in cystic fibrosis. Paediatr Respir Rev. 2013;Jun 13; Epub ahead of print. [PMID: 23769887 DOI: 10.1016/j.prrv.2013.05.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Castellani C, Assael BM. Cystic fibrosis: a clinical view. Cell Mol Life Sci. 2017;74:129-140. [PMID: 27709245 DOI: 10.1007/s00018-016-2393-9] [Cited by in Crossref: 96] [Cited by in F6Publishing: 85] [Article Influence: 16.0] [Reference Citation Analysis]
2 Cheng K, Ashby D, Smyth RL. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev 2017;9:CD000222. [PMID: 28891588 DOI: 10.1002/14651858.CD000222.pub4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
3 Tam PKH, Yiu RS, Lendahl U, Andersson ER. Cholangiopathies - Towards a molecular understanding. EBioMedicine 2018;35:381-93. [PMID: 30236451 DOI: 10.1016/j.ebiom.2018.08.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
4 Poetter-Lang S, Staufer K, Baltzer P, Tamandl D, Muin D, Bastati N, Halilbasic E, Hodge JC, Trauner M, Kazemi-Shirazi L, Ba-Ssalamah A. The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study. Eur Radiol 2019;29:1048-58. [PMID: 30054796 DOI: 10.1007/s00330-018-5650-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
5 Wilbert F, Grünert SC, Heinzmann A, Bode SFN. Cystic fibrosis in disguise - the wolf in sheep's clothing, a case report. BMC Pediatr 2021;21:174. [PMID: 33853553 DOI: 10.1186/s12887-021-02636-w] [Reference Citation Analysis]
6 Cheng K, Ashby D, Smyth RL. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev 2014;:CD000222. [PMID: 25501301 DOI: 10.1002/14651858.CD000222.pub3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
7 Ramnath D, Irvine KM, Lukowski SW, Horsfall LU, Loh Z, Clouston AD, Patel PJ, Fagan KJ, Iyer A, Lampe G, Stow JL, Schroder K, Fairlie DP, Powell JE, Powell EE, Sweet MJ. Hepatic expression profiling identifies steatosis-independent and steatosis-driven advanced fibrosis genes. JCI Insight 2018;3:120274. [PMID: 30046009 DOI: 10.1172/jci.insight.120274] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
8 Al Sinani S, Al-Mulaabed S, Al Naamani K, Sultan R. Cystic Fibrosis Liver Disease: Know More. Oman Med J 2019;34:482-9. [PMID: 31745411 DOI: 10.5001/omj.2019.90] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ramsey ML, Wellner MR, Porter K, Kirkby SE, Li SS, Lara LF, Kelly SG, Hanje AJ, Sobotka LA. Cystic fibrosis patients on cystic fibrosis transmembrane conductance regulator modulators have a reduced incidence of cirrhosis. World J Hepatol 2022; 14(2): 411-419 [DOI: 10.4254/wjh.v14.i2.411] [Reference Citation Analysis]
10 Sieloff EM, Rutledge B, Huffman C, Vos D, Melgar T. National trends and outcomes of genetically inherited non-alcoholic chronic liver disease in the USA: estimates from the National Inpatient Sample (NIS) database. Gastroenterol Rep (Oxf) 2021;9:38-48. [PMID: 33747525 DOI: 10.1093/gastro/goaa091] [Reference Citation Analysis]
11 Hohenester S, Beuers U. [Chronic cholestatic liver diseases : Differential diagnosis, pathogenesis and current treatment in adults]. Internist (Berl) 2017;58:805-25. [PMID: 28721532 DOI: 10.1007/s00108-017-0287-z] [Reference Citation Analysis]
12 Zhu X, Zhang B, He Y, Bao J. Liver Organoids: Formation Strategies and Biomedical Applications. Tissue Eng Regen Med 2021;18:573-85. [PMID: 34132985 DOI: 10.1007/s13770-021-00357-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ogawa M, Ogawa S, Bear CE, Ahmadi S, Chin S, Li B, Grompe M, Keller G, Kamath BM, Ghanekar A. Directed differentiation of cholangiocytes from human pluripotent stem cells. Nat Biotechnol. 2015;33:853-861. [PMID: 26167630 DOI: 10.1038/nbt.3294] [Cited by in Crossref: 171] [Cited by in F6Publishing: 153] [Article Influence: 24.4] [Reference Citation Analysis]
14 Burke A, Smith D, Coulter C, Bell SC, Thomson R, Roberts JA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis. Clin Pharmacokinet 2021. [PMID: 33982266 DOI: 10.1007/s40262-021-01010-4] [Reference Citation Analysis]
15 De Palma FDE, Raia V, Kroemer G, Maiuri MC. The Multifaceted Roles of MicroRNAs in Cystic Fibrosis. Diagnostics (Basel) 2020;10:E1102. [PMID: 33348555 DOI: 10.3390/diagnostics10121102] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Baldassarre A, Felli C, Prantera G, Masotti A. Circulating microRNAs and Bioinformatics Tools to Discover Novel Diagnostic Biomarkers of Pediatric Diseases. Genes (Basel) 2017;8:E234. [PMID: 28925938 DOI: 10.3390/genes8090234] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
17 Meurer SK, Alsamman M, Scholten D, Weiskirchen R. Endoglin in liver fibrogenesis: Bridging basic science and clinical practice. World J Biol Chem 2014; 5(2): 180-203 [PMID: 24921008 DOI: 10.4331/wjbc.v5.i2.180] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
18 Dos Santos ALM, de Melo Santos H, Nogueira MB, Távora HTO, de Lourdes Jaborandy Paim da Cunha M, de Melo Seixas RBP, de Freitas Velloso Monte L, de Carvalho E. Cystic Fibrosis: Clinical Phenotypes in Children and Adolescents. Pediatr Gastroenterol Hepatol Nutr 2018;21:306-14. [PMID: 30345244 DOI: 10.5223/pghn.2018.21.4.306] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
19 Fiorotto R, Amenduni M, Mariotti V, Fabris L, Spirli C, Strazzabosco M. Src kinase inhibition reduces inflammatory and cytoskeletal changes in ΔF508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy. Hepatology 2018;67:972-88. [PMID: 28836688 DOI: 10.1002/hep.29400] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
20 Bono-Neri F, Romano C, Isedeh A. Cystic Fibrosis: Advancing Along the Continuum. J Pediatr Health Care 2019;33:242-54. [PMID: 30529125 DOI: 10.1016/j.pedhc.2018.08.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Tchoukaev A, Taytard J, Rousselet N, Rebeyrol C, Debray D, Blouquit-Laye S, Moisan MP, Foury A, Guillot L, Corvol H, Tabary O, Le Rouzic P. Opposite Expression of Hepatic and Pulmonary Corticosteroid-Binding Globulin in Cystic Fibrosis Patients. Front Pharmacol 2018;9:545. [PMID: 29922157 DOI: 10.3389/fphar.2018.00545] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]